Canada - English - Health Canada

aa pharma inc - ipratropium bromide - solution - 250mcg - ipratropium bromide 250mcg - antimuscarinics antispasmodics

Canada - English - Health Canada

teva canada limited - ipratropium bromide - solution - 250mcg - ipratropium bromide 250mcg - antimuscarinics antispasmodics

Canada - English - Health Canada

boehringer ingelheim (canada) ltd ltee - ipratropium bromide - metered-dose aerosol - 20mcg - ipratropium bromide 20mcg - antimuscarinics antispasmodics

Canada - English - Health Canada

boehringer ingelheim (canada) ltd ltee - tiotropium (tiotropium bromide monohydrate); olodaterol (olodaterol hydrochloride) - solution - 2.5mcg; 2.5mcg - tiotropium (tiotropium bromide monohydrate) 2.5mcg; olodaterol (olodaterol hydrochloride) 2.5mcg - antimuscarinics antispasmodics

United States - English - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - glycopyrrolate (unii: v92so9wp2i) (glycopyrronium - unii:a14fb57v1d) - glycopyrrolate 15.6 ug - seebri™ neohaler® is indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema. seebri neohaler is contraindicated in patients who have demonstrated hypersensitivity to glycopyrrolate or to any of the ingredients [see warnings and precautions (5.3)] . teratogenic effects: pregnancy category c there are no adequate and well-controlled studies with seebri neohaler in pregnant women. because animal reproduction studies are not always predictive of human response, seebri neohaler should only be used during pregnancy if the potential benefit to the patient justifies the potential risk to the fetus. women should be advised to contact their physician if they become pregnant while taking seebri neohaler. glycopyrrolate was not teratogenic in wistar rats and new zealand white rabbits at approximately 1400 and 530 times, respectively, the mrhd in adults (on an auc basis at maternal inhaled doses

United States - English - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals inc. - tiotropium bromide monohydrate (unii: l64sxo195n) (tiotropium - unii:0eb439235f), olodaterol hydrochloride (unii: 65r445w3v9) (olodaterol - unii:vd2ysn1afd) - tiotropium 3.124 ug - stiolto respimat is a combination of tiotropium and olodaterol indicated for long-term, once-daily maintenance treatment of patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema. important limitations of use - stiolto respimat is not indicated to treat acute deteriorations of copd [see warnings and precautions (5.2)]. - stiolto respimat is not indicated to treat asthma. the safety and effectiveness of stiolto respimat in asthma have not been established. use of a laba, including stiolto respimat, without an inhaled corticosteroid is contraindicated in patients with asthma [see warnings and precautions (5.1)] . stiolto respimat is not indicated for the treatment of asthma. stiolto respimat is contraindicated in patients with a hypersensitivity to tiotropium, ipratropium, olodaterol, or any component of this product [see warnings and precautions (5.4)] . in clinical trials and postmarketing experience with tiotropium, immediate hypersensitivity reactions, inc

United States - English - NLM (National Library of Medicine)

astrazeneca pharmaceuticals lp - glycopyrrolate (unii: v92so9wp2i) (glycopyrronium - unii:a14fb57v1d), formoterol fumarate (unii: w34shf8j2k) (formoterol - unii:5zz84gcw8b) - glycopyrrolate 9 ug - bevespi aerosphere is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd). limitations of use: bevespi aerosphere is not indicated for the relief of acute bronchospasm or for the treatment of asthma [see warnings and precautions (5.1, 5.2)] . bevespi aerosphere is contraindicated in: risk summary   there are no adequate and well-controlled trials of bevespi aerosphere or its individual components, glycopyrrolate and formoterol fumarate, in pregnant women to inform a drug-associated risk. in animal reproduction studies, glycopyrrolate alone, administered by the subcutaneous route in rats and rabbits, did not cause structural abnormalities or affect fetal survival at exposures approximately 2700 and 5400 times from the maximum recommended human daily inhalation dose (mrhdid), respectively. glycopyrrolate had no effects on the physical, functional, and behavioral development of rat pups with exposures up to 2700 times the mrhdid. formoterol fumarate alone, admin

Australia - English - Department of Health (Therapeutic Goods Administration)

btc speciality health pty ltd - mannitol, quantity: 0 mg - capsule, hard - excipient ingredients: gelatin - aridol is indicated for identifying bronchial hyperresponsiveness to assist in the diagnosis of asthma.

United States - English - NLM (National Library of Medicine)

sunovion pharmaceuticals inc. - indacaterol maleate (unii: 2jec1itx7r) (indacaterol - unii:8or09251mq), glycopyrrolate (unii: v92so9wp2i) (glycopyrronium - unii:a14fb57v1d) - indacaterol 27.5 ug - utibron® neohaler® is a combination of indacaterol and glycopyrrolate indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema. important limitations of use: utibron neohaler is not indicated for the relief of acute bronchospasm or for the treatment of asthma [see warnings and precautions (5.1, 5.2)] . the safety and effectiveness of utibron in asthma have not been established. use of a laba, including utibron neohaler, without an inhaled corticosteroid is contraindicated in patients with asthma [see warnings and precautions (5.1)] . utibron neohaler is not indicated for the treatment of asthma. utibron neohaler is contraindicated in patients who have demonstrated hypersensitivity to indacaterol, glycopyrrolate, or to any of the ingredients [see warnings and precautions (5.5)] . teratogenic effects: pregnancy category c there are no adequate and well-controlled studies with utibron

Canada - English - Health Canada

boehringer ingelheim (canada) ltd ltee - tiotropium (tiotropium bromide monohydrate) - solution - 2.5mcg - tiotropium (tiotropium bromide monohydrate) 2.5mcg - antimuscarinics antispasmodics